| Autor: |
Miyoshi, Toru, Doi, Masayuki, Hirohata, Satoshi, Kamikawa, Shigeshi, Usui, Shinichi, Ogawa, Hiroko, Sakane, Kosuke, Izumi, Reishi, Ninomiya, Yoshifumi, Kusachi, Shozo |
| Předmět: |
|
| Zdroj: |
Heart & Vessels; Jul2011, Vol. 26 Issue 4, p408-413, 6p |
| Abstrakt: |
dipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type 1 receptor blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients with hypertension. Thirty patients newly diagnosed with essential hypertension were treated with olmesartan (20 mg/day), an ARB, for 6 months. Serum levels of A-FABP and high-sensitivity C-reactive protein (hsCRP) were examined and the cardio-ankle vascular index (CAVI), which is a marker of arterial stiffness, was also determined. Serum A-FABP at baseline was significantly correlated with the body mass index ( r = 0.45, P = 0.01), homeostasis model assessment as a marker of insulin resistance ( r = 0.53, P < 0.01), and systolic blood pressure ( r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein cholesterol, triglyceride, and CAVI. Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure. Multiple regression analysis revealed that the change in CAVI was independently correlated with the change in serum A-FABP. Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink